⌕
Agios Pharmaceuticals · AGIO · Nasdaq
Tenet 64 · Solid
Compare
$30.15−4.56%At closeTenet 64 · Solid
$30.15−1.44 (−4.56%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Agios Pharmaceuticals (AGIO) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

2 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~56.0%/yr (FY22→FY25), net margin −764.0%. Worth your attention in FY25: Capex step-up ($4.3M). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲48.0%
54.0
FY22→FY25CAGR +56.0%/yr
Net income ($M)—
−412.8
FY21→FY25CAGR —
Free cash flow ($M)▲3.6%
−377.3
capex stepped upCAGR —
Diluted EPS—
−7.12
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−4.1%

60.4mn → 58.0mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex step-up
$4.3M

▲156% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)54.0Revenue−6.3COGS47.7Gross profit−339.5R&D−180.3SG&A−472.1Op income59.4Tax & other−412.8Net income

-764¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
185013889254630%sector median net margin ~4%FY21FY25

Net margin -764.0% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
140.854.036.526.814.20.0▲48.0%+56.0% (22→25)
Cost of revenue
8.76.34.22.91.70.0▲52.3%+55.0% (22→25)
Gross profit
132.147.732.323.912.5—A▲47.5%+56.1%
Research & development
343.4339.5301.3295.5279.9257.0▲12.7%+7.2%
Selling, general & admin
208.0180.3156.8119.9121.7121.4▲15.0%+10.4%
Total operating expenses
551.4519.8458.1415.4401.6378.4▲13.5%+8.3%
Operating incomefeeds ROC rank
−419.3−472.1−425.7−391.5−389.0−378.4▼10.9%—
Other income, net
45.758.31,143.739.4157.221.9——
Pretax income
−373.6−413.8718.0−352.1−231.8−356.5——
Income tax
—−1.044.20.00.0———
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−372.9−412.8673.7−352.1−231.81,604.7——
Per share
Diluted EPSbuyback-sensitive
−6.33−7.1211.64−6.33−4.2326.55——
Diluted shares (mn)
59.7157.9757.8955.6554.7960.45▲0.1%−1.0%
Margins
Gross margin90th pct in Healthcare
93.8%88.3%88.6%89.3%88.0%—A▼0.3pp+0.2pp
Operating margin
−297.7%−873.9%−1166.5%−1459.5%−2732.1%—▲292.6pp+1858.2pp
Net margin6th pct in Healthcare
−264.8%−764.0%1845.9%−1312.6%−1627.8%—▼2609.9pp+863.8pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY11 – FY20 · 10 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 10 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Agios Pharmaceuticals' revenue last fiscal year?

Agios Pharmaceuticals reported revenue of $54.0M in fiscal 2025, up 48.0% from fiscal 2024.

What was Agios Pharmaceuticals' net income?

Agios Pharmaceuticals reported net income of −$412.8M in fiscal 2025, a net margin of −764.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.